biote Corp.(BTMD.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
biote Corp.
BTMD.US
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
4.837 T
BTMD.USMarket value -Rank by Market Cap -/-

Financial Score

19/01/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking88/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-28.36%E
    • Profit Margin14.72%B
    • Gross Margin71.77%A
  • Growth ScoreB
    • Revenue YoY1.34%C
    • Net Profit YoY300.58%A
    • Total Assets YoY9.95%B
    • Net Assets YoY48.38%A
  • Cash ScoreC
    • Cash Flow Margin679.46%C
    • OCF YoY1.34%C
  • Operating ScoreA
    • Turnover1.84A
  • Debt ScoreE
    • Gearing Ratio158.81%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    biote Corp. | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 47.96 M

    LB filings·
    US
    BTMD
    -2.93%
    LB filings·
    US
    BTMD
    -2.93%

    Roth MKM Sticks to Their Buy Rating for biote (BTMD)

    Roth MKM analyst George Kelly has reaffirmed a Buy rating for biote (BTMD) with a price target of $4.50. Kelly, a 4-star analyst, has an average return of 5.7% and a 46.07% success rate. Additionally, TD Cowen's Jonna Kim also issued a Buy rating for biote today, while B. Riley Securities maintained a Hold rating on the stock.

    Tip Ranks·
    US
    BTMD
    -2.93%
    Tip Ranks·
    US
    BTMD
    -2.93%

    Biote Corp reports results for the quarter ended September 30 - Earnings Summary

    Biote Corp reported Q3 earnings of 22 cents per share, down from 33 cents last year, and below analysts' expectations of 5 cents. Revenue decreased by 6.7% to $47.96 million, slightly above the expected $47.76 million. The company’s net income was $8.19 million. Biote shares fell 4.7% this quarter and 53.7% year-to-date. Analysts maintain a "buy" rating, with a 12-month price target of $5.28, 44.5% above the last closing price of $2.93.

    Reuters·
    US
    BTMD
    -2.93%
    Reuters·
    US
    BTMD
    -2.93%

    biote Corp. | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 47.96 M

    LB filings·
    US
    BTMD
    -2.93%
    LB filings·
    US
    BTMD
    -2.93%

    Biote Corporation reports third quarter revenue of $48.0 million and net income of $9.2 million

    Biote Corporation reported third quarter 2025 revenue of $48.0 million, down 6.7% from the previous year. Procedure revenue decreased by 10.4%, while dietary supplements revenue increased by 8.4%. Gross profit margin improved to 71.8%. Net income was $9.2 million, with diluted earnings per share of $0.22, compared to $12.7 million and $0.33 per share last year. Adjusted EBITDA fell 20.5% to $12.9 million, and the company repurchased about one million shares, maintaining its 2025 financial guidance.

    Reuters·
    US
    BTMD
    -2.93%
    Reuters·
    US
    BTMD
    -2.93%
    © 2026 Longbridge｜Disclaimer